General ~ Prophylactic Surgery
~ Genetics of Breast & Ovarian Cancer

List was last updated on Oct 10, 2019 @ 2:30 pm.


    • Interventions to improve psychosocial well-being in female BRCA-mutation carriers following risk-reducing surgery.
    • Jeffers L, Reid J, Fitzsimons D, Morrison PJ, Dempster M.
    • Cochrane Database Syst Rev. 2019 Oct 9;10:CD012894. doi: 10.1002/14651858.CD012894.pub2. [Epub ahead of print]
    • Review

    Original research:

    Mindfulness-based stress reduction for menopausal symptoms after risk-reducing salpingo-oophorectomy (PURSUE study): a randomised controlled trial.

    Original research:

    Addressing sexual dysfunction after risk-reducing salpingo-oophorectomy: effects of a brief, psychosexual intervention.

    • A Cost-effectiveness Analysis of Multigene Testing for All Patients With Breast Cancer.
    • Sun L, Brentnall A, Patel S, Buist DSM, Bowles EJA, Evans DGR, Eccles D, Hopper J, Li S, Southey M, Duffy S, Cuzick J, Dos Santos Silva I, Miners A, Sadique Z, Yang L, Legood R, Manchanda R.
    • JAMA Oncol. 2019 Oct 3. doi: 10.1001/jamaoncol.2019.3323. [Epub ahead of print]

    CME Audio Interview: Cost-effectiveness of Multigene Testing for All Patients With Breast Cancer. (JN Learning : JAMA Oncology)

    Press: Study Finds Breast, Ovarian Cancer Gene Tests Cost-Effective for Unselected Breast Cancer Patients. (GenomeWeb)

    • Broad Application of Multigene Panel Testing for Breast Cancer Susceptibility-Pandora's Box Is Opening Wider.
    • Robson M, Domchek S.
    • JAMA Oncol. 2019 Oct 3. doi: 10.1001/jamaoncol.2019.4004. [Epub ahead of print]
    • Commentary
    • Cost effectiveness of bilateral risk-reducing mastectomy and salpingo-oophorectomy.
    • Schrauder MG, Brunel-Geuder L, Häberle L, Wunderle M, Hoyer J, Csorba R, Reis A, Schulz-Wendtland R, Beckmann MW, Lux MP.
    • Eur J Med Res. 2019 Sep 14;24(1):32. doi: 10.1186/s40001-019-0391-8.
    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.
    • US Preventive Services Task Force, Owens DK, Davidson KW, Krist AH, Barry MJ, Cabana M, Caughey AB, Doubeni CA, Epling JW Jr, Kubik M, Landefeld CS, Mangione CM, Pbert L, Silverstein M, Simon MA, Tseng CW, Wong JB.
    • JAMA. 2019 Aug 20;322(7):652-665. doi: 10.1001/jama.2019.10987.

    Evidence report, Review:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    Guidelines [Internet]:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].

    Editorial:

    Broadening Criteria for BRCA1/2 Evaluation: Placing the USPSTF Recommendation in Context.

    Editorial:

    USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan.

    Editorial:

    Hereditary Cancer Evaluation in 2019-a Rapidly Evolving Landscape.

    Editorial:

    US Preventive Services Task Force Breast Cancer Recommendation Statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer.

    News:

    USPSTF Calls for More BRCA Screening.

    Patient Page:

    Should I Be Tested for BRCA Mutations?

    Audio Interview, CME Activity: USPSTF Recommendation: Assessment, Counseling, and Testing for BRCA-Related Cancer. (JAMA)

    Press: USPSTF Recommendations on BRCA Mutation Testing. (Medscape Oncology)

    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
    • Nelson HD, Pappas M, Cantor A, Haney E, Holmes R.
    • JAMA. 2019 Aug 20;322(7):666-685. doi: 10.1001/jama.2019.8430.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].

    • Should I Be Tested for BRCA Mutations?
    • Jin J.
    • JAMA. 2019 Aug 20;322(7):702. doi: 10.1001/jama.2019.11251.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • USPSTF Recommendation: Assessment, Counseling, and Testing for BRCA-Related Cancer.
    • Mangione CM.
    • JAMA. 2019 Aug 20.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    • Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA1/2-Related Cancer in Women: A Systematic Review for the U.S. Preventive Services Task Force [Internet].
    • Nelson HD, Pappas M, Cantor A, Haney E, Holmes R, Stillman L.
    • Rockville (MD): Agency for Healthcare Research and Quality (US); 2019 Aug. Report No.: 19-05251-EF-1. U.S. Preventive Services Task Force Evidence Syntheses, formerly Systematic Evidence Reviews.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer: US Preventive Services Task Force Recommendation Statement.

    Guidelines:

    Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-Related Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.

    • Screening and surgical prophylaxis for hereditary cancer syndromes with high risk of endometrial and ovarian cancer.
    • Bercow AS, Eisenhauer EL.
    • J Surg Oncol. 2019 Jul 29. doi: 10.1002/jso.25645. [Epub ahead of print]
    • Review
    • A young woman's story of genetic testing and risk-reducing mastectomy.
    • [No author given]
    • FORCE. XRAYS. 2019 Jun 6.

    Narrative: I Had a Preventive Mastectomy—Then Found Out I Already Had Breast Cancer. (Health)

    • [Recommendations for Preventive Care for Women with Rare Genetic Cause of Breast and Ovarian Cancer.]
    • Foretová L, Navrátilová M, Svoboda M, Vašíčková P, Sťahlová EH, Házová J, Kleiblová P, Kleibl Z, Macháčková E, Palácová M, Petráková K.
    • Klin Onkol. 2019 Summer;32(Supplementum2):6-13. doi: 10.14735/amko2019S6.
    • Cancer Genomics for Oncologists: Cancer Risk and Management of BRCA1 and BRCA2 Carriers.
    • George A.
    • Curr Genet Med Rep. 2019 May 9. doi: 10.1007/s40142-019-00167-6. [Epub ahead of print]
    • Review
    • Five screening-detected breast cancer cases in initially disease-free BRCA1 or BRCA2 mutation carriers.
    • Shimada S, Yoshida R, Nakashima E, Kitagawa D, Gomi N, Horii R, Takeuchi S, Ashihara Y, Kita M, Akiyama F, Ohno S, Saito M, Arai M.
    • Breast Cancer. 2019 Apr 12. doi: 10.1007/s12282-019-00971-6. [Epub ahead of print]
    • Economic modeling of risk-adapted screen-and-treat strategies in women at high risk for breast or ovarian cancer.
    • Müller D, Danner M, Schmutzler R, Engel C, Wassermann K, Stollenwerk B, Stock S, Rhiem K.
    • Eur J Health Econ. 2019 Feb 21. doi: 10.1007/s10198-019-01038-1. [Epub ahead of print]
    • Optimise not compromise: The importance of a multidisciplinary breast cancer patient pathway in the era of oncoplastic and reconstructive surgery.
    • Strach MC, Prasanna T, Kirova YM, Alran S, O'Toole S, Beith JM, Poortmans P, McNeil CM, Carroll S.
    • Crit Rev Oncol Hematol. 2019 Feb;134:10-21. doi: 10.1016/j.critrevonc.2018.11.007. Epub 2018 Nov 30.
    • Review
    • Selected medical interventions in women with a deleterious BRCA mutation: a population-based study in British Columbia.
    • Hanley GE, McAlpine JN, Cheifetz R, Schrader KA, McCullum M, Huntsman D.
    • Curr Oncol. 2019 Feb;26(1):e17-e23. doi: 10.3747/co.26.4068. Epub 2019 Feb 1.
    • Perioperative Management of Women Undergoing Risk-reducing Surgery for Hereditary Breast and Ovarian Cancer.
    • AlHilli MM, Al-Hilli Z.
    • J Minim Invasive Gynecol. 2019 Feb;26(2):253-265. doi: 10.1016/j.jmig.2018.09.767. Epub 2018 Sep 19.
    • Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
    • Franceschini G, Di Leone A, Terribile D, Sanchez MA, Masetti R.
    • Ann Ital Chir. 2019;90:1-2.
    • Review
    • No. 366-Gynaecologic Management of Hereditary Breast and Ovarian Cancer.
    • Jacobson M, Bernardini M, Sobel ML, Kim RH, McCuaig J, Allen L.
    • J Obstet Gynaecol Can. 2018 Nov;40(11):1497-1510. doi: 10.1016/j.jogc.2018.05.046.
    • Guidelines

    [Article in French]:

    No 366 - Prise en charge gynécologique du cancer du sein et de l'ovaire héréditaire.

    • Risk-Reducing Options for Women with a Hereditary Breast Cancer Predisposition.
    • Jatoi I.
    • Eur J Breast Health. 2018 Oct 1;14(4):189-193. doi: 10.5152/ejbh.2018.4324. eCollection 2018 Oct.

    Letter, Review:

    What The Surgeons Should Know About The Bilateral Prophylactic Mastectomy in BRCA Mutation Carriers.

    • Germline and somatic genetic testing in ovarian cancer patients.
    • Chandrasekaran D, Manchanda R.
    • BJOG. 2018 Oct;125(11):1460. doi: 10.1111/1471-0528.15225. Epub 2018 May 10.
    • Commentary
    • Surgery for BRCA, TP53 and PALB2: a literature review.
    • Song CV, Teo SH, Taib NA, Yip CH.
    • Ecancermedicalscience. 2018 Aug 29;12:863. doi: 10.3332/ecancer.2018.863. eCollection 2018.
    • Breast Cancer Surgical Risk Reduction for Patients With Inherited Mutations in Moderate Penetrance Genes.
    • Weiss A, Garber JE, King T.
    • JAMA Surg. 2018 Aug 29. doi: 10.1001/jamasurg.2018.2493. [Epub ahead of print]
    • Review
    • Concurrent risk-reduction surgery in patients with increased lifetime risk for breast and ovarian cancer: an analysis of the National Surgical Quality Improvement Program (NSQIP) database.
    • Elmi M, Azin A, Elnahas A, McCready DR, Cil TD.
    • Breast Cancer Res Treat. 2018 Aug;171(1):217-223. doi: 10.1007/s10549-018-4818-7. Epub 2018 May 14.
    • Reducing the Risk of Gynecologic Cancer in Hereditary Breast Ovarian Cancer Syndrome Mutation Carriers: Moral Dilemmas and the Principle of Double Effect.
    • Casey MJ, Salzman TA.
    • Linacre Q. 2018 Aug;85(3):225-240. doi: 10.1177/0024363918788340. Epub 2018 Jul 20.
    • A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer-Reply to letter to the editor by Petelin et al.
    • Li Y, Devlin JJ.
    • Value Health. 2018 Jul;21(7):893-894. doi: 10.1016/j.jval.2018.02.010. Epub 2018 Apr 5.
    • Letter

    Letter:

    Heterogeneity and Uncertainties Specific to Genome-Based Health Technological Assessments.

    Original Research:

    A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.

    • BRCA Mutations in the Young, High-Risk Female Population: Genetic Testing, Management of Prophylactic Therapies, and Implications for Plastic Surgeons.
    • Salibian AA, Frey JD, Choi M, Karp NS.
    • Plast Reconstr Surg. 2018 Jun;141(6):1341-1350. doi: 10.1097/PRS.0000000000004363.
    • Cost-effectiveness of different strategies to prevent breast and ovarian cancer in German women with a BRCA 1 or 2 mutation.
    • Müller D, Danner M, Rhiem K, Stollenwerk B, Engel C, Rasche L, Borsi L, Schmutzler R, Stock S.
    • Eur J Health Econ. 2018 Apr;19(3):341-353. doi: 10.1007/s10198-017-0887-5. Epub 2017 Apr 5.
    • Germline & somatic genetic testing in ovarian cancer patients.
    • Chandrasekaran D, Manchanda R.
    • BJOG. 2018 Mar 25. doi: 10.1111/1471-0528.15225. [Epub ahead of print]
    • Commentary
    • Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
    • Yamauchi H, Nakagawa C, Kobayashi M, Kobayashi Y, Mano T, Nakamura S, Arai M.
    • Breast Cancer. 2018 Mar;25(2):141-150. doi: 10.1007/s12282-017-0803-y. Epub 2017 Oct 10.
    • Recommendations and Choices for BRCA Mutation Carriers at Risk for Ovarian Cancer: A Complicated Decision.
    • Lewis KE, Lu KH, Klimczak AM, Mok SC.
    • Cancers (Basel). 2018 Feb 21;10(2). pii: E57. doi: 10.3390/cancers10020057.
    • Management of hereditary breast and ovarian cancer.
    • Yamauchi H, Takei J.
    • Int J Clin Oncol. 2018 Feb;23(1):45-51. doi: 10.1007/s10147-017-1208-9. Epub 2017 Nov 28.
    • Review
    • Considerations in Testing for Inherited Breast Cancer Predisposition in the Era of Personalized Medicine.
    • Powers B, Pal T, Laronga C.
    • Surg Oncol Clin N Am. 2018 Jan;27(1):1-22. doi: 10.1016/j.soc.2017.08.003.
    • Review
    • Prophylactic Surgery: For Whom, When and How?
    • Mau C, Untch M.
    • Breast Care (Basel). 2017 Dec;12(6):379-384. doi: 10.1159/000485830. Epub 2017 Dec 13.
    • Non-BRCA1/2 Breast Cancer Susceptibility Genes: A New Frontier with Clinical Consequences for Plastic Surgeons.
    • Frey JD, Salibian AA, Schnabel FR, Choi M, Karp NS.
    • Plast Reconstr Surg Glob Open. 2017 Nov 20;5(11):e1564. doi: 10.1097/GOX.0000000000001564. eCollection 2017 Nov.
    • Sexual Health Is Paramount in the Counseling of Women at Risk for Breast or Ovarian Cancer Undergoing Risk-Reducing Surgery.
    • Rullo JE, Pruthi S.
    • J Natl Compr Canc Netw. 2017 Nov 1;15(11):1297. doi: 10.6004/jnccn.2017.7016.
    • Commentary
    • Current and future role of genetic screening in gynecologic malignancies.
    • Ring KL, Garcia C, Thomas MH, Modesitt SC.
    • Am J Obstet Gynecol. 2017 Nov;217(5):512-521. doi: 10.1016/j.ajog.2017.04.011. Epub 2017 Apr 12.
    • What about prophylactic surgery in BRCA1/BRCA2 mutation carriers? Observations from an Italian pilot study.
    • Dionigi F, Maffoni M, Ferrari A, Garcia-Etienne CA, Ricciardi A, Razzaboni E, Sgarella A, Trotti E.
    • Breast J. 2017 Nov;23(6):766-767. doi: 10.1111/tbj.12825. Epub 2017 Jun 2.
    • Letter
    • Integrating surgery and genetic testing for the modern surgeon.
    • Caso R, Beamer M, Lofthus AD, Sosin M.
    • Ann Transl Med. 2017 Oct;5(20):399. doi: 10.21037/atm.2017.06.50.
    • Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers.
    • Lee YC, Milne RL, Lheureux S, Friedlander M, McLachlan SA, Martin KL, Bernardini MQ, Smith C, Picken S, Nesci S, Hopper JL, Phillips KA; Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab).
    • Eur J Cancer. 2017 Oct;84:114-120. doi: 10.1016/j.ejca.2017.07.004. Epub 2017 Aug 10.
    • Risk Reduction Strategies in Breast Cancer Prevention.
    • Costa M, Saldanha P.
    • Eur J Breast Health. 2017 Jul 1;13(3):103-112. doi: 10.5152/ejbh.2017.3583. eCollection 2017 Jul.
    • Practice Patterns of Hereditary Ovarian Cancer Management in Korea.
    • Choi MC, Lim MC, Lee M, Kim MK, Suh DH, Song YJ, Kim TJ, Chang SJ, Kim JW.
    • Int J Gynecol Cancer. 2017 May 12. doi: 10.1097/IGC.0000000000000964. [Epub ahead of print]
    • Cost-effectiveness of risk-reducing surgeries in preventing hereditary breast and ovarian cancer.
    • Schrauder MG, Brunel-Geuder L, Häberle L, Wunderle M, Hoyer J, Reis A, Schulz-Wendtland R, Beckmann MW, Lux MP.
    • Breast. 2017 Apr;32:186-191. doi: 10.1016/j.breast.2017.02.008. Epub 2017 Feb 17.
    • A Multigene Test Could Cost-Effectively Help Extend Life Expectancy for Women at Risk of Hereditary Breast Cancer.
    • Li Y, Arellano AR, Bare LA, Bender RA, Strom CM, Devlin JJ.
    • Value Health. 2017 Apr;20(4):547-555. doi: 10.1016/j.jval.2017.01.006. Epub 2017 Feb 23.

    Letter:

    Heterogeneity and Uncertainties Specific to Genome-Based Health Technological Assessments.

    Letter:

    A multigene test could cost-effectively help extend life expectancy for women at risk of hereditary breast cancer-Reply to letter to the editor by Petelin et al.

    • A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.
    • Eccleston A, Bentley A, Dyer M, Strydom A, Vereecken W, George A, Rahman N.
    • Value Health. 2017 Apr;20(4):567-576. doi: 10.1016/j.jval.2017.01.004. Epub 2017 Mar 3.
    • A brother and sister with breast cancer, BRCA2 mutations and bilateral supernumerary nipples.
    • McKay M, Coad R.
    • Ann Transl Med. 2017 Mar;5(5):106. doi: 10.21037/atm.2017.03.02.
    • BRCA mutation genetic testing implications in the United States.
    • Bayraktar S, Arun B.
    • Breast. 2017 Feb;31:224-232. doi: 10.1016/j.breast.2016.11.021. Epub 2016 Dec 6.
    • Outcomes of Concurrent Breast and Gynecologic Risk Reduction Surgery.
    • Ma IT, Gray RJ, Wasif N, Butler KA, Cornella JL, Magrina JF, Magtibay PM, Casey WJ, Mahabir R, Rebecca AM, Hunt KS, Pockaj BA.
    • Ann Surg Oncol. 2017 Jan;24(1):77-83. doi: 10.1245/s10434-016-5479-6. Epub 2016 Aug 31.
    • The effect of referral for genetic counseling on genetic testing and surgical prevention in women at high risk for ovarian cancer: Results from a randomized controlled trial.
    • Drescher CW, Beatty JD, Resta R, Andersen MR, Watabayashi K, Thorpe J, Hawley S, Purkey H, Chubak J, Hanson N, Buist DSM, Urban N.
    • Cancer. 2016 Nov 15;122(22):3509-3518. doi: 10.1002/cncr.30190. Epub 2016 Jul 22.
    • Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review.
    • Ludwig KK, Neuner J, Butler A, Geurts JL, Kong AL.
    • Am J Surg. 2016 Oct;212(4):660-669. doi: 10.1016/j.amjsurg.2016.06.010. Epub 2016 Jul 18.
    • Review
    • Identification and management of women with a family history of breast cancer: Practical guide for clinicians.
    • Heisey R, Carroll JC.
    • Can Fam Physician. 2016 Oct;62(10):799-803.
    • Management of women with a hereditary predisposition for breast cancer.
    • Jatoi I, Benson JR.
    • Future Oncol. 2016 Oct;12(19):2277-88. doi: 10.2217/fon-2016-0186. Epub 2016 Jul 7.
    • Review
    • Müllerian intra-abdominal carcinomatosis in hereditary breast ovarian cancer syndrome: implications for risk-reducing surgery.
    • Casey MJ, Colanta AB.
    • Fam Cancer. 2016 Jul;15(3):371-84. doi: 10.1007/s10689-016-9878-4.
    • Review
    • Women's Health Issues for BRCA Mutation Carriers.
    • Sabatini ME, Ellisen LW.
    • Am Soc Clin Oncol Educ Book. 2016 May;(36):14-17. doi: 10.1200/EDBK_100001.
    • Podcast: Making Prophylactic Surgery Decisions.
    • Ellen T. Matloff.
    • My Gene Counsel. 2016 Feb 24.
    • The Role of Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.
    • Hartmann LC, Lindor NM.
    • N Engl J Med. 2016 Feb 4;374(5):454-68. doi: 10.1056/NEJMra1503523.
    • Review

    Comment, Letter

    Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.

    Comment, Letter

    Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.

    Comment, Letter

    Risk-Reducing Surgery in Hereditary Breast and Ovarian Cancer.

    News: Better Approaches to Patient Counseling of BRCA Gene Mutation Carriers Needed. (Oncology Nurse Advisor)

    • Genetic/Familial High-Risk Assessment: Breast and Ovarian, Version 2.2015.
    • Daly MB, Pilarski R, Axilbund JE, Berry M, Buys SS, Crawford B, Farmer M, Friedman S, Garber JE, Khan S, Klein C, Kohlmann W, Kurian A, Litton JK, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Rana H, Reiser G, Robson ME, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wick MJ, Wiesner GL, Dwyer M, Kumar R, Darlow S.
    • J Natl Compr Canc Netw. 2016 Feb;14(2):153-62.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: NCCN High-Risk Breast-Ovarian Guidelines 1.2016

    • Surgical Decision Making in the BRCA-Positive Population: Institutional Experience and Comparison with Recent Literature.
    • Flippo-Morton T, Walsh K, Chambers K, Amacker-North L, White B, Sarantou T, Boselli DM, White RL Jr.
    • Breast J. 2016 Jan-Feb;22(1):35-44. doi: 10.1111/tbj.12521. Epub 2015 Dec 23.
    • Women's Health Issues for BRCA Mutation Carriers.
    • Sabatini ME, Ellisen LW.
    • Am Soc Clin Oncol Educ Book. 2016;35:14-17. doi: 10.14694/EDBK_100001.

    Comments from NSGC Discussion Forum Cancer SIG

    Subject: hormonal birth control with ATM mutations?

    • [Gynecological Care and Prevention of Gynecological Malignancies in BRCA1 and BRCA2 Mutation Carriers].
    • Zikán M.
    • Klin Onkol. 2015 Winter;29 Suppl 1:22-30.
    • Review, [Article in Czech]
    • How medical choices influence quality of life of women carrying a BRCA mutation.
    • Harmsen MG, Hermens RP, Prins JB, Hoogerbrugge N, de Hullu JA.
    • Crit Rev Oncol Hematol. 2015 Dec;96(3):555-68. doi: 10.1016/j.critrevonc.2015.07.010. Epub 2015 Jul 26.
    • Risk-reducing surgery in BRCA 1/2 mutation carries: a point of view.
    • De Felice F, Marchetti C.
    • Oncotarget. 2015 Nov 24;6(37):39391-2. doi: 10.18632/oncotarget.6348.
    • The Genetics of Breast Cancer: What the Surgical Oncologist Needs to Know.
    • Weitzel JN.
    • Surg Oncol Clin N Am. 2015 Oct;24(4):705-732. doi: 10.1016/j.soc.2015.06.011.
    • Review
    • A Rare Case of BRCA2-Associated Breast Cancer in Pregnancy.
    • Leidhin CN, Heeney A, Connolly C, Swan N, Foster A, Geraghty J.
    • Ir Med J. 2015 Jul-Aug;108(7):217-8.
    • Breast Cancer Risk Reduction, Version 2.2015.
    • Bevers TB, Ward JH, Arun BK, Colditz GA, Cowan KH, Daly MB, Garber JE, Gemignani ML, Gradishar WJ, Jordan JA, Korde LA, Kounalakis N, Krontiras H, Kumar S, Kurian A, Laronga C, Layman RM, Loftus LS, Mahoney MC, Merajver SD, Meszoely IM, Mortimer J, Newman L, Pritchard E, Pruthi S, Seewaldt V, Specht MC, Visvanathan K, Wallace A, Bergman MA, Kumar R.
    • J Natl Compr Canc Netw. 2015 Jul;13(7):880-915.
    • Practice guideline
    • Should risk-reducing surgery in women from hereditary breast ovarian cancer families be confined to removal of the fallopian tubes with ovarian conservation?
    • Snyder CL, Casey MJ, Lynch HT.
    • Womens Health (Lond Engl). 2015 Jul;11(4):423-7. doi: 10.2217/whe.15.26. Epub 2015 Aug 6.
    • Editorial / Commentary
    • Recommendations and Reality: What Personal Stories of Hereditary Cancer Can Tell Us.
    • Ridgely Fisk Green, Katrina Trivers.
    • CDC. Genomics and Health Impact Blog. 2015 Jun 1.
    • The Consequences of a BRCA Mutation in Women.
    • Famorca-Tran J, Roux G.
    • J Adv Pract Oncol. 2015 May-Jun;6(3):194-210. Epub 2015 May 1.
    • Risk-reducing surgery in hereditary gynecological cancer: Clinical applications in Lynch syndrome and hereditary breast and ovarian cancer.
    • Adachi M, Banno K, Yanokura M, Iida M, Nakamura K, Nogami Y, Umene K, Masuda K, Kisu I, Ueki A, Hirasawa A, Tominaga E, Aoki D.
    • Mol Clin Oncol. 2015 Mar;3(2):267-273. Epub 2014 Nov 20.
    • A comprehensive approach to the identification and management of the BRCA patient.
    • Garcia C, Powell CB.
    • Obstet Gynecol Surv. 2015 Feb;70(2):131-43. doi: 10.1097/OGX.0000000000000156.
    • Review
    • Hereditary cancer syndromes with high risk of endometrial and ovarian cancer: Surgical options for personalized care.
    • McCann GA, Eisenhauer EL.
    • J Surg Oncol. 2015 Jan;111(1):118-24. doi: 10.1002/jso.23743. Epub 2014 Aug 20.
    • Review
    • Breast Cancer Following Ovarian Cancer in BRCA Mutation Carriers.
    • Gangi A, Cass I, Paik D, Barmparas G, Karlan B, Dang C, Li A, Walsh C, Rimel BJ, Amersi FF.
    • JAMA Surg. 2014 Dec 1;149(12):1306-1313. doi: 10.1001/jamasurg.2014.1081.

    Comments on NSGC Discussion Forum Cancer SIG

    Subject: Breast cancer risk in ovarian cancer survivors

    Subject: BRCA+ ovarian ca dx- breast ca risk and outcomes

    Letter

    Effect of Breast Cancer After Ovarian Cancer on Mortality for BRCA Mutation Carriers.

    Letter, Reply

    Effect of Breast Cancer After Ovarian Cancer on Mortality for BRCA Mutation Carriers-Reply.

    • BRCA genetic testing: State of the science.
    • Kelly PA, Connors LM.
    • Nurse Pract. 2014 Nov 16;39(11):9. doi: 10.1097/01.NPR.0000456025.48460.c5.
    • Letter, Comment

    Review:

    Genetic testing for BRCA1 and BRCA2 genes.

    • [Current Clinical Issues and Recent Trends in Hereditary Breast and Ovarian Cancer in Japan-Genetic Testing for HBOC and Risk-Reducing Surgery].
    • Arai M, Iwase T, Takazawa Y, Takeshima N.
    • Gan To Kagaku Ryoho. 2014 Nov;41(11):1333-9.
    • Review, [Article in Japanese]
    • Current strategies for the prevention of breast cancer.
    • Advani P, Moreno-Aspitia A.
    • Breast Cancer (Dove Med Press). 2014 May 2;6:59-71. doi: 10.2147/BCTT.S39114. eCollection 2014.
    • Management of women at high risk of breast cancer.
    • Armstrong AC, Evans GD.
    • BMJ. 2014 Apr 28;348:g2756. doi: 10.1136/bmj.g2756.
    • Review
    • Did we need a new Angelina Jolie to discuss about prophylactic surgery for colon cancer because of Mister Lynch's silence?
    • Pocard M.
    • J Visc Surg. 2014 Feb;151(1):1-2. doi: 10.1016/j.jviscsurg.2013.11.001. Epub 2013 Dec 25.
    • Biography, Editorial
    • Honing the Health Message on BRCA Mutations.
    • Schmidt C.
    • J Natl Cancer Inst. 2013 Dec 18;105(24):1843-4. doi: 10.1093/jnci/djt364. Epub 2013 Dec 6.
    • Tubal ligation, hysterectomy and epithelial ovarian cancer in the New England Case-Control Study.
    • Rice MS, Murphy MA, Vitonis AF, Cramer DW, Titus LJ, Tworoger SS, Terry KL.
    • Int J Cancer. 2013 Nov 15;133(10):2415-21. doi: 10.1002/ijc.28249. Epub 2013 Jul 9.
    • Local approaches to hereditary breast cancer.
    • Cooper BT, Murphy JO, Sacchini V, Formenti SC.
    • Ann Oncol. 2013 Nov;24 Suppl 8:viii54-viii60. doi: 10.1093/annonc/mdt327.
    • Challenging and complex decisions in the management of the BRCA mutation carrier.
    • Stan DL, Shuster LT, Wick MJ, Swanson CL, Pruthi S, Bakkum-Gamez JN.
    • J Womens Health (Larchmt). 2013 Oct;22(10):825-34. doi: 10.1089/jwh.2013.4407. Epub 2013 Aug 29.
    • [Characteristics of selected clinical features in BRCA1 mutation carriers affected with breast cancer undergoing preventive female genital tract surgeries].
    • Menkiszak J, Chudecka-Głaz A, Gronwald J, Bedner R, Cymbaluk-Płoska A, Wezowska M, Zielińska D, Rzepka-Górska I.
    • Ginekol Pol. 2013 Sep;84(9):758-64.
    • First Man Has Prostatectomy Because of BRCA Gene Mutation.
    • Zosia Chustecka.
    • Medscape Medical News. Oncology. 2013 May 20.
    • [Choices for women at risk of hereditary breast cancer].
    • Saadatmand S, Obdeijn IM, Koppert LB, Tilanus-Linthorst M.
    • Ned Tijdschr Geneeskd. 2013;157(43):A6625.
    • Case report, Review, [Article in Dutch]
    • [Methods of surgical prevention of breast cancer and of ovarian cancer in BRCA mutation carriers].
    • Bit-Sava EM, Belogurova MB, Imianitov EN, Balandov SG, Korniushin OV, Borisov MK.
    • Vopr Onkol. 2013;59(2):5-11.
    • Review, [Article in Russian]
    • [Prophylactic surgery in common hereditary cancer syndromes].
    • Noguès C, Mouret-Fourme E.
    • Bull Acad Natl Med. 2012 Oct;196(7):1237-45.
    • Risk-reducing Surgery in Women at Risk for Familial Breast or Ovarian Cancer.
    • Rhiem K, Pfeifer K, Schmutzler RK, Kiechle M.
    • Geburtshilfe Frauenheilkd. 2012 Sep;72(9):833-839.
    • A simulation model to predict the impact of prophylactic surgery and screening on the life expectancy of BRCA1 and BRCA2 mutation carriers.
    • Sigal BM, Munoz DF, Kurian AW, Plevritis SK.
    • Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1066-77. doi: 10.1158/1055-9965.EPI-12-0149. Epub 2012 May 3.
    • Managing the breast in patients who test positive for hereditary breast cancer.
    • Euhus D.
    • Ann Surg Oncol. 2012 Jun;19(6):1738-44. doi: 10.1245/s10434-012-2258-x. Epub 2012 Mar 7.
    • Review
    • Practice Patterns of Hereditary Ovarian Cancer Management in Korea.
    • Choi MC, Lim MC, Lee M, Kim MK, Suh DH, Song YJ, Kim TJ, Chang SJ, Kim JW.
    • Int J Gynecol Cancer. 2017 Jun;27(5):895-899. doi: 10.1097/IGC.0000000000000964.
    • Prevention of breast cancer in the context of a national breast screening programme.
    • Howell A, Astley S, Warwick J, Stavrinos P, Sahin S, Ingham S, McBurney H, Eckersley B, Harvie M, Wilson M, Beetles U, Warren R, Hufton A, Sergeant J, Newman W, Buchan I, Cuzick J, Evans DG.
    • J Intern Med. 2012 Apr;271(4):321-30. doi: 10.1111/j.1365-2796.2012.02525.x.